Target intelligence / Profile preview

Human hepatocyte surface receptors (CD81, SR-BI, EphA2) (CD81/SR-BI/EphA2)

Target
CD81/SR-BI/EphA2
Molecular classification
Tetraspanin, Scavenger receptor, Receptor tyrosine kinase
01

Overview

Human hepatocyte surface receptors, primarily CD81, SR-BI, and EphA2, serve as critical entry factors for Plasmodium falciparum sporozoites, including the 7G8 strain, during the liver stage of malaria infection. CD81 is a member of the tetraspanin family and is essential for the formation of the parasitophorous vacuole, a membrane-bound compartment where the parasite replicates. SR-BI and EphA2 also contribute to the invasion process, with their importance varying depending on the parasite strain and host environment. These receptors are considered high-value therapeutic targets for malaria prevention, as blocking their interaction with sporozoite surface proteins (such as P36 and P52) can prevent the establishment of infection. Research into these receptors often involves the use of monoclonal antibodies or small molecules to inhibit parasite entry, providing a foundation for pre-erythrocytic vaccine and drug development.

Other names
CD81Cluster of Differentiation 81TAPA-1Tetraspanin-28SR-BIScavenger receptor class B type IEphA2Ephrin type-A receptor 2
02

Mechanism of action

Blockade of host-pathogen protein-protein interaction

03

Biological functions

Cell adhesionCell-cell signalingHost-pathogen interactionMembrane organizationViral and parasitic entry
04

Disease associations

MalariaInfectionHepatitis C
05

Safety considerations

Potential for off-target effects on normal physiological functions of CD81 (e.g., immune response)Risk of interfering with lipid metabolism (SR-BI)Potential toxicity from systemic receptor blockade
06

Interacting drugs

Anti-CD81 monoclonal antibodies

2 more in the full profile.

07

Biomarkers

CD81 expression levelsSR-BI expression levelsEphA2 expression levels

Beyond the preview

Go deeper on Human hepatocyte surface receptors (CD81, SR-BI, EphA2) (CD81/SR-BI/EphA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human hepatocyte surface receptors (CD81, SR-BI, EphA2) (CD81/SR-BI/EphA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call